$BNTC
Benitec Biopharma Inc.

2023 Q2 Form 10-Q Financial Statement

#000119312523144211 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $10.00K $54.00K $48.00K
YoY Change 12.5% 4700.0%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $48.00K
YoY Change -580.0%
Gross Profit Margin 100.0%
Selling, General & Admin $1.370M $1.228M $1.337M
YoY Change -11.78% -8.15% 29.81%
% of Gross Profit 2785.42%
Research & Development $3.190M $3.167M $2.171M
YoY Change 0.44% 45.88% -21.28%
% of Gross Profit 4522.92%
Depreciation & Amortization $32.00K $54.00K
YoY Change -40.74% -19.4%
% of Gross Profit 112.5%
Operating Expenses $4.560M $4.395M $3.508M
YoY Change -3.57% 25.29% -7.54%
Operating Profit -$4.341M -$3.460M
YoY Change 25.46% -8.78%
Interest Expense -$30.00K -$7.000K $214.0K
YoY Change -89.25% -103.27% -10800.0%
% of Operating Profit
Other Income/Expense, Net -$80.00K -$56.00K -$29.00K
YoY Change 60.0% 93.1% -75.0%
Pretax Income -$4.660M -$4.397M -$3.275M
YoY Change -8.03% 34.26% -16.24%
Income Tax
% Of Pretax Income
Net Earnings -$4.660M -$4.397M -$3.275M
YoY Change -8.03% 34.26% -16.22%
Net Earnings / Revenue -46600.0% -8142.59% -6822.92%
Basic Earnings Per Share -$0.16 -$0.40
Diluted Earnings Per Share -$2.83 -$0.16 -$400.8K
COMMON SHARES
Basic Shares Outstanding 27.98M 27.98M 8.172M
Diluted Shares Outstanding 27.98M 8.172M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.480M $6.551M $8.630M
YoY Change -38.95% -24.09% -28.02%
Cash & Equivalents $2.500M $6.600M $8.630M
Short-Term Investments
Other Short-Term Assets $1.184M $774.0K $206.0K
YoY Change 59.78% 275.73% -49.63%
Inventory
Prepaid Expenses $1.280M $332.0K
Receivables $60.00K $56.00K $5.000K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.729M $7.395M $8.841M
YoY Change -22.63% -16.36% -28.74%
LONG-TERM ASSETS
Property, Plant & Equipment $87.00K $106.0K $1.042M
YoY Change -60.81% -89.83% 85.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $97.00K $105.0K $181.0K
YoY Change -28.15% -41.99% -8.12%
Total Long-Term Assets $735.0K $825.0K $1.223M
YoY Change -36.25% -32.54% 19.78%
TOTAL ASSETS
Total Short-Term Assets $3.729M $7.395M $8.841M
Total Long-Term Assets $735.0K $825.0K $1.223M
Total Assets $4.464M $8.220M $10.06M
YoY Change -25.26% -18.32% -25.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.140M $635.0K $100.0K
YoY Change 170.14% 535.0% -93.9%
Accrued Expenses $2.770M $2.482M $1.753M
YoY Change 35.85% 41.59% 182.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.978M $3.153M $1.909M
YoY Change 57.11% 65.17% -21.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $280.0K $354.0K $635.0K
YoY Change -49.91% -44.25% 1170.0%
Total Long-Term Liabilities $280.0K $354.0K $635.0K
YoY Change -49.91% -44.25% 1170.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.978M $3.153M $1.909M
Total Long-Term Liabilities $280.0K $354.0K $635.0K
Total Liabilities $4.262M $3.507M $2.544M
YoY Change 37.88% 37.85% 1.84%
SHAREHOLDERS EQUITY
Retained Earnings -$167.9M -$163.2M
YoY Change 13.19%
Common Stock $168.9M $168.8M
YoY Change 10.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $202.0K $4.713M $7.520M
YoY Change
Total Liabilities & Shareholders Equity $4.464M $8.220M $10.06M
YoY Change -25.26% -18.32% -25.05%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.660M -$4.397M -$3.275M
YoY Change -8.03% 34.26% -16.22%
Depreciation, Depletion And Amortization $32.00K $54.00K
YoY Change -40.74% -19.4%
Cash From Operating Activities -$4.090M -$4.029M -$3.422M
YoY Change -15.76% 17.74% 71.96%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -4.090M -4.029M -3.422M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -4.090M -4.029M -3.422M
YoY Change -15.98% 17.74% 71.1%
FREE CASH FLOW
Cash From Operating Activities -$4.090M -$4.029M -$3.422M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$4.090M -$3.422M
YoY Change -15.53% 72.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4620206
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001808898
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39267
dei Entity Registrant Name
EntityRegistrantName
BENITEC BIOPHARMA INC.
dei Entity Address Address Line1
EntityAddressAddressLine1
3940 Trust Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
780-0819
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
BNTC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27981161
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6551000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4062000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
56000
CY2022Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
774000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
741000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
7395000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
4820000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
222000
CY2023Q1 us-gaap Deposit Assets
DepositAssets
25000
CY2022Q2 us-gaap Deposit Assets
DepositAssets
25000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
589000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
771000
CY2023Q1 us-gaap Assets
Assets
8220000
CY2022Q2 us-gaap Assets
Assets
5973000
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2455000
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1880000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
429000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
400000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
269000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3153000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2532000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
354000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
559000
CY2023Q1 us-gaap Liabilities
Liabilities
3507000
CY2022Q2 us-gaap Liabilities
Liabilities
3091000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27981161
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27981161
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8171690
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8171690
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168791000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
152453000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163228000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148327000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-853000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1245000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4713000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2882000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8220000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5973000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
54000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
48000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
68000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
73000
CY2023Q1 us-gaap Revenues
Revenues
54000
CY2022Q1 us-gaap Revenues
Revenues
48000
us-gaap Revenues
Revenues
68000
us-gaap Revenues
Revenues
73000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3167000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2171000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9588000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8096000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1228000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1337000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5011000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5093000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4395000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3508000
us-gaap Operating Expenses
OperatingExpenses
14599000
us-gaap Operating Expenses
OperatingExpenses
13189000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4341000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3460000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14531000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13116000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-45000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
229000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-391000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
36000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-10000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-25000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-22000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4000
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-5000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-10000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-56000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
185000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-370000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4397000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3275000
us-gaap Net Income Loss
NetIncomeLoss
-14901000
us-gaap Net Income Loss
NetIncomeLoss
-13141000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
45000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-233000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
392000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-51000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
45000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-233000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
392000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-51000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4352000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3508000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14509000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13192000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4397000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3275000
us-gaap Net Income Loss
NetIncomeLoss
-14901000
us-gaap Net Income Loss
NetIncomeLoss
-13141000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27981161
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27981161
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8171690
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8171690
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22090191
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22090191
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8171690
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8171690
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20010000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
239000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5045000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15475000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
239000
CY2021Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-57000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-4821000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10836000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
192000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-233000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3275000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7520000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2882000
CY2022Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1869000
CY2022Q3 bntc Issuance And Exercise Of Prefunded And Common Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
16015000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
302000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
507000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5093000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14613000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-48000
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-160000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5411000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8994000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
71000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
45000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4397000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4713000
us-gaap Net Income Loss
NetIncomeLoss
-14901000
us-gaap Net Income Loss
NetIncomeLoss
-13141000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
115000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
161000
bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
182000
bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
168000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-10000
us-gaap Share Based Compensation
ShareBasedCompensation
325000
us-gaap Share Based Compensation
ShareBasedCompensation
702000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
50000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-47000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-609000
bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
580000
bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
512000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
30000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
28000
bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-188000
bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-140000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13917000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11044000
bntc Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants
ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants
17884000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1869000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16015000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
391000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-95000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2489000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11139000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4076000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19769000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6565000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8630000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
794000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-11-22
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use of Estimates </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, allowance for uncollectable receivables, foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates, and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. <br/></div> </div>
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
6565000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
4076000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concentrations of Risk </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40684965
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
845159
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
161000
us-gaap Net Income Loss
NetIncomeLoss
-14900000
us-gaap Net Income Loss
NetIncomeLoss
-13100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11000000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6600000
CY2023Q1 us-gaap Due From Banks
DueFromBanks
6551000
CY2022Q2 us-gaap Due From Banks
DueFromBanks
4062000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
332000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
871000
CY2023Q1 bntc Credit Memo
CreditMemo
546000
CY2023Q1 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2022Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
5000
CY2023Q1 us-gaap Other Assets
OtherAssets
879000
CY2022Q2 us-gaap Other Assets
OtherAssets
876000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
774000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
741000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1403000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1404000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1297000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1182000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
222000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
115000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
CY2023Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
635000
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
422000
CY2023Q1 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
116000
CY2022Q2 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
120000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
53000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131000
CY2023Q1 bntc Accrued Opmd Project Costs Current
AccruedOpmdProjectCostsCurrent
-1560000
CY2022Q2 bntc Accrued Opmd Project Costs Current
AccruedOpmdProjectCostsCurrent
-1089000
CY2023Q1 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
55000
CY2022Q2 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
47000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
36000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
71000
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2455000
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1880000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
771000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
182000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
589000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
811000
us-gaap Operating Lease Payments
OperatingLeasePayments
188000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
623000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
354000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
269000
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P2Y2M15D
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0467
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
292000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
303000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
62000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
657000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
623000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
107095
CY2022Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
10.5
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
42088194
CY2022Q3 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
0.49
CY2022Q4 bntc Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
2171628
CY2022Q4 bntc Weightedaverageexercisepriceofclassofwarrantsorrightsexercised
Weightedaverageexercisepriceofclassofwarrantsorrightsexercised
0.0001
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
39916566
CY2023Q1 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
0.52
bntc Class Of Warrants Or Rights Excercisable
ClassOfWarrantsOrRightsExcercisable
39916566
bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable
0.52
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.66
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
39916566
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
71000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
325000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
702000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
200000

Files In Submission

Name View Source Status
0001193125-23-144211-index-headers.html Edgar Link pending
0001193125-23-144211-index.html Edgar Link pending
0001193125-23-144211.txt Edgar Link pending
0001193125-23-144211-xbrl.zip Edgar Link pending
bntc-20230331.xsd Edgar Link pending
d214466d10q.htm Edgar Link pending
d214466dex311.htm Edgar Link pending
d214466dex312.htm Edgar Link pending
d214466dex321.htm Edgar Link pending
d214466dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g214466g20n20.jpg Edgar Link pending
g214466g21n21.jpg Edgar Link pending
g214466g23n23.jpg Edgar Link pending
g214466g24n01.jpg Edgar Link pending
g214466g24n02.jpg Edgar Link pending
g214466g25n25.jpg Edgar Link pending
g214466g26n01.jpg Edgar Link pending
g214466g26n02.jpg Edgar Link pending
g214466g27n27.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
bntc-20230331_def.xml Edgar Link unprocessable
bntc-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d214466d10q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bntc-20230331_cal.xml Edgar Link unprocessable
bntc-20230331_lab.xml Edgar Link unprocessable